About Angsana Molecular and Diagnostics
Angsana Molecular and Diagnostics is a Healthcare company based in Singapore (Singapore) founded in 2014 by Chris Tan, and was acquired by Parkway Pantai in July 2017. Genomic assays for oncology, immunology, and pharmacogenomics are provided. Its chief executive, as recorded, is Chris Tan. The company was acqui-hired. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its legal entity is PARKWAY PANTAI LIMITED.
Company details
Angsana Molecular and Diagnostics was established in 2014 in Singapore. Genomic assays are offered in the diagnostics sector, focusing on oncology, immunology, and pharmacogenomics. Molecular and genetic profiling are integrated to address innate immunity and support individualized medicine prescriptions. Additional tests are provided for oncology applications, prenatal and postnatal fetal and maternal assessments, allergies, and pharmacogenetics, with operations centered in Singapore.
- Headquarters Singapore, Singapore
- Founders Chris Tan
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website angsanadx.com
- Social LinkedIn
- Acquired by Parkway Pantai (Jul 2017)
- Legal Name Parkway Pantai Limited
- Investors
- Acquired byParkway Pantai
(Jul 2017)
Investors in Angsana Molecular and Diagnostics
Angsana Molecular and Diagnostics has secured backing from 1 investor. Prominent investors backing the company include Parkway Pantai.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A chain of multispecialty hospitals is operated in Singapore. | 2011 | parkwaypantai.com | Singapore, Singapore |
Investor details for Angsana Molecular and Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Angsana Molecular and Diagnostics
1 people are tracked at Angsana Molecular and Diagnostics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Chris Tan | Founder & CEO | Leadership |
Complete people profiles for Angsana Molecular and Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Angsana Molecular and Diagnostics
2 dated milestones of Angsana Molecular and Diagnostics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Angsana Molecular and Diagnostics is founded.
- Exit Acquired by Parkway Pantai.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Angsana Molecular and Diagnostics
Angsana Molecular and Diagnostics was founded in 2014.
Angsana Molecular and Diagnostics is headquartered in Singapore, Singapore.
Chris Tan is the CEO of Angsana Molecular and Diagnostics, as recorded in our data. They have also founded this company.
Angsana Molecular and Diagnostics was established in 2014 in Singapore. Genomic assays are offered in the diagnostics sector, focusing on oncology, immunology, and pharmacogenomics. Molecular and genetic profiling are integrated to address innate immunity and support individualized medicine prescriptions. Additional tests are provided for oncology applications, prenatal and postnatal fetal and maternal assessments, allergies, and pharmacogenetics, with operations centered in Singapore.
Angsana Molecular and Diagnostics has 1 investor. Key investors include Parkway Pantai.
Angsana Molecular and Diagnostics operates through Parkway Pantai Limited.
Yes. Angsana Molecular and Diagnostics was acquired by Parkway Pantai in July 2017.